FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2741802976> ?p ?o ?g. }

• W2741802976 endingPage "e21515" @default.
• W2741802976 startingPage "e21515" @default.
• W2741802976 abstract "e21515 Background: In our previous study, the presence of c-kit mutation as well as tumor size and mitotic count was an independent poor risk factor for relapse after curative resection of primary localized GIST. The patients with all the 3 poor risk factors had only 30% of 2 year relapse free survival rate (RFSR). (Kim, et al. Clin Cancer Res, 2004) It is also well known that c-kit exon 11 mutant GISTs respond better to imatinib treatment than the other mutant or wild type GISTs. Therefore, the patients who have primary localized GISTs with large size, high mitotic count, and c-kit exon 11 mutation may be the best candidate of adjuvant imatinib treatment. In this phase II study, we have evaluated the efficacy and safety of adjuvant imatinib for this patient group. Methods: Patients who underwent complete resection of a primary GIST with 1) c-kit exon 11 mutation, and 2) ≥10 mitoses/50 HPF, or tumor size ≥10 cm, or ≥5 mitoses/50 HPF and tumor size ≥5 cm were eligible. Patients received imatinib 400mg p.o. daily until recurrence of disease, intolerable toxicities, or for 2 years. The primary end point was relapse-free survival (RFS). Results: A total of 47 patients from 4 centers in Korea were enrolled. The median age was 57.0 years. Stomach was the most common primary site (n=31). Median primary tumor size was 7.5cm and median mitoses index was 12/50 HPF. With a median follow-up of 26.9 months, the median RFS and overall survival (OS) have not yet been reached. RFSR was 97.7% at 1-year and 92.7% at 2-years. Six relapses (12.8%) were documented among the 47 patients. The treatments were generally well tolerated. Grade 3–4 toxicities included neutropenia 27.7%, rash 8.5%, constipation 4.3%, anorexia 2.1%, vomiting 2.1%, and pruritis 2.1%. There were no episode of febrile neutropenia and treatment-related death. Conclusions: Postoperative adjuvant imatinib for 2 years were safe and could prolong the RFS in patients with high-risk of recurrence following complete surgical resection of the primary GIST. However, it remains unknown if this benefit in RFS can be translated into OS benefit. So, further follow-up is needed with comparison of OS with historical controls who could be use imatinib after recurrence. [Table: see text]" @default.
• W2741802976 created "2017-08-08" @default.
• W2741802976 creator A5005925636 @default.
• W2741802976 creator A5011840042 @default.
• W2741802976 creator A5017838060 @default.
• W2741802976 creator A5021126729 @default.
• W2741802976 creator A5027233624 @default.
• W2741802976 creator A5043743755 @default.
• W2741802976 creator A5047772418 @default.
• W2741802976 creator A5048964340 @default.
• W2741802976 creator A5059766169 @default.
• W2741802976 creator A5091587460 @default.
• W2741802976 date "2009-05-20" @default.
• W2741802976 modified "2023-10-11" @default.
• W2741802976 title "A phase II study of imatinib mesylate as adjuvant treatment for curatively resected high-risk localized gastrointestinal stromal tumors" @default.
• W2741802976 doi "https://doi.org/10.1200/jco.2009.27.15_suppl.e21515" @default.
• W2741802976 hasPublicationYear "2009" @default.
• W2741802976 type Work @default.
• W2741802976 sameAs 2741802976 @default.
• W2741802976 citedByCount "16" @default.
• W2741802976 countsByYear W27418029762012 @default.
• W2741802976 countsByYear W27418029762013 @default.
• W2741802976 countsByYear W27418029762015 @default.
• W2741802976 countsByYear W27418029762016 @default.
• W2741802976 countsByYear W27418029762017 @default.
• W2741802976 crossrefType "journal-article" @default.
• W2741802976 hasAuthorship W2741802976A5005925636 @default.
• W2741802976 hasAuthorship W2741802976A5011840042 @default.
• W2741802976 hasAuthorship W2741802976A5017838060 @default.
• W2741802976 hasAuthorship W2741802976A5021126729 @default.
• W2741802976 hasAuthorship W2741802976A5027233624 @default.
• W2741802976 hasAuthorship W2741802976A5043743755 @default.
• W2741802976 hasAuthorship W2741802976A5047772418 @default.
• W2741802976 hasAuthorship W2741802976A5048964340 @default.
• W2741802976 hasAuthorship W2741802976A5059766169 @default.
• W2741802976 hasAuthorship W2741802976A5091587460 @default.
• W2741802976 hasConcept C121608353 @default.
• W2741802976 hasConcept C126322002 @default.
• W2741802976 hasConcept C141071460 @default.
• W2741802976 hasConcept C143998085 @default.
• W2741802976 hasConcept C16930146 @default.
• W2741802976 hasConcept C203092338 @default.
• W2741802976 hasConcept C2775922572 @default.
• W2741802976 hasConcept C2777583451 @default.
• W2741802976 hasConcept C2777982462 @default.
• W2741802976 hasConcept C2778729363 @default.
• W2741802976 hasConcept C2779013556 @default.
• W2741802976 hasConcept C2780283643 @default.
• W2741802976 hasConcept C3019892230 @default.
• W2741802976 hasConcept C535046627 @default.
• W2741802976 hasConcept C71924100 @default.
• W2741802976 hasConcept C90924648 @default.
• W2741802976 hasConceptScore W2741802976C121608353 @default.
• W2741802976 hasConceptScore W2741802976C126322002 @default.
• W2741802976 hasConceptScore W2741802976C141071460 @default.
• W2741802976 hasConceptScore W2741802976C143998085 @default.
• W2741802976 hasConceptScore W2741802976C16930146 @default.
• W2741802976 hasConceptScore W2741802976C203092338 @default.
• W2741802976 hasConceptScore W2741802976C2775922572 @default.
• W2741802976 hasConceptScore W2741802976C2777583451 @default.
• W2741802976 hasConceptScore W2741802976C2777982462 @default.
• W2741802976 hasConceptScore W2741802976C2778729363 @default.
• W2741802976 hasConceptScore W2741802976C2779013556 @default.
• W2741802976 hasConceptScore W2741802976C2780283643 @default.
• W2741802976 hasConceptScore W2741802976C3019892230 @default.
• W2741802976 hasConceptScore W2741802976C535046627 @default.
• W2741802976 hasConceptScore W2741802976C71924100 @default.
• W2741802976 hasConceptScore W2741802976C90924648 @default.
• W2741802976 hasIssue "15_suppl" @default.
• W2741802976 hasLocation W27418029761 @default.
• W2741802976 hasOpenAccess W2741802976 @default.
• W2741802976 hasPrimaryLocation W27418029761 @default.
• W2741802976 hasRelatedWork W1966631138 @default.
• W2741802976 hasRelatedWork W1994675184 @default.
• W2741802976 hasRelatedWork W2079083600 @default.
• W2741802976 hasRelatedWork W2151926537 @default.
• W2741802976 hasRelatedWork W2223383871 @default.
• W2741802976 hasRelatedWork W2390643041 @default.
• W2741802976 hasRelatedWork W2484960040 @default.
• W2741802976 hasRelatedWork W2771867163 @default.
• W2741802976 hasRelatedWork W2977381871 @default.
• W2741802976 hasRelatedWork W4385580344 @default.
• W2741802976 hasVolume "27" @default.
• W2741802976 isParatext "false" @default.
• W2741802976 isRetracted "false" @default.
• W2741802976 magId "2741802976" @default.
• W2741802976 workType "article" @default.